Quick Links: Skip to main page content Skip to Search Skip to Topics Menu Skip to Common Links
  • Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals
  • Print
  • Share
  • E-mail
-
Generic Name: talquetamab-tgvs
Trade Name: Talvey
Date Designated: 05/03/2021
Orphan Designation: Treatment of Multiple Myeloma
Orphan Designation Status: Designated/Approved
Janssen Biotech, inc.
800/850 Ridgeview Dr.
Horsham, Pennsylvania 19044
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: talquetamab-tgvs
Trade Name: Talvey
Marketing Approval Date: 08/09/2023
Approved Labeled Indication: treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
Exclusivity End Date: 08/09/2030 
Exclusivity Protected Indication* :  treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody
*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-